Loestrin 24 Generic Pay-for-Delay Suit Tossed Over Lack of Cash Payments

Drug Industry Daily
A federal judge has tossed out all claims in a consolidated class-action antitrust lawsuit alleging that brandmaker Warner Chilcott executed a “reverse payment” to generics firms Watson (now Actavis) and Lupin Pharmaceuticals to delay generic competition on its contraceptive Loestrin 24.

To View This Article:


Subscribe To Drug Industry Daily